Product Name: Akt1 (305-311) pT305+pT308
Product Number: PE-04AYJ00
Peptide Name: Akt1 (305-311) pT305+pT308
Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases and for epitope mapping of phosphosite-specific antibodies. The peptide sequence is located in the protein kinase catalytic domain activation T-loop between subdomains VII and VIII. Phosphorylation of the T308 site stimulates phosphotransferase activity.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: pT-MK-pT-FCG
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 945.92 Da
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Scientific Background: Akt1 (PKBA) is a protein-serine/threonine kinase of the AGC group and Akt family. It is normally inactive in the cytoplasm. When PI3K is activated by extracellular growth factors, Akt1 is recruited to the cell membrane and phosphorylated by PDK1, mTOR and other protein kinases to become active. This leads to the induction of survival, proliferation, angiogenesis and metabolism pathways. Akt1 is also involved in cell-cycle progression via its inhibitory phosphorylation of cyclin-dependent kinases and activatory phosphorylation of mTOR. This kinase is highly expressed in most tested human tissues. Orthologues of Akt are conserved in a wide range of animals, plants and unicellular eukaryotes. Phosphorylation of T72, S124,S129, S246, T308, Y315,Y326, T450, S473 and Y474 increases Akt1 phosphotransferase activity. TRAF6-induced 'K63'-linked Akt1 ubiquitination is critical for phosphorylation and activation. Phosphorylation of T34 inhibits phosphotransferase activity. Akt1 has been implicated in a wide range of human cancers, including lymphomas, breast, lung, colorectal, pancreatic and prostate cancers.